Acute lymphoblastic leukemia (ALL) cells are particularly poor at generating anti-leukemia immunity, despite residing in lymphoid organs. To assess a potential role of dendritic cells (DC) in poor anti-leukemia immunity, we analyzed peripheral blood DC in 55 pediatric ALL patients at the time of initial diagnosis and 19 age-matched healthy controls. Dendritic cells were identified by their expression of HLA-DR, lack of B, T, NK, and monocyte markers, and expression of CD11c (myeloid DC(mDC)) or BDCA-2 (plasmacytoid DC(pDC)) using flow cytometry. We found that in children with B-lineage ALL, numbers of both mDC and pDC were significantly reduced (P ¼ 0.0001). In contrast, T-lineage ALL patients showed normal pDC and significantly elevated mDC (P ¼ 0.003) levels, with normal expression of HLA-DR and co-stimulatory molecules. A decrease in DC could not be explained by general impairment of myelopoiesis, as we could not demonstrate a correlation of DC numbers with granulocyte/monocyte numbers in patients with B-lineage ALL. However, aberrant expression of myeloid surface markers on leukemic blasts was frequent in patients lacking myeloid DC indicating a potential block of DC differentiation. Thus, depletion of DC in B-lineage ALL patients may contribute to poor anti-leukemia immune responses.
Introduction
Acute lymphoblastic leukemia (ALL) represents the most common malignancy in children. Despite advances in risk stratification and risk-adapted chemotherapeutic treatment, about 20% of patients eventually suffer from disease relapse. [1] [2] [3] Experience from allogeneic bone marrow transplantation in pediatric ALL indicates that strong anti-leukemia immune responses, such as graft-versus-leukemia effects, are associated with increased disease-free survival. 4, 5 However, several investigators have demonstrated poor in vivo anti-leukemia immune responses in ALL patients, even in the bone marrow as the primary site of disease. 6 Strategies to induce anti-leukemia T-cell responses ex vivo have utilized activation of ALL blasts, 7 addition of cytokines and priming of T cells using professional or engineered antigen-presenting cells. 8 Dendritic cells (DC) represent the key initiators of immune responses in vivo. Defects in DC function have been demonstrated in several other diseases of either viral infection (chronic hepatitis C, 9 HIV infection 10 ) or leukemic malignancies (acute myeloid leukemia, 11 chronic myelogenous leukemia, 12 hairy cell leukemia 13 ). Recently, Mami et al. 14 showed reduced DC in a group of adult and pediatric patients with B-cell precursor ALL. Thus, defects in dendritic cells may impact on poor antileukemia immune responses in patients with childhood ALL.
We reasoned that quantitative and/or qualitative aberrations in DC might reflect impaired immunity in children with ALL. Here, we show a significant reduction of peripheral blood DC (pbDC) in pediatric patients with B-precursor ALL. Furthermore, we demonstrate that aberrant expression of myeloid surface markers on leukemic blasts is common in patients with lack of myeloid DC (mDC) and may point toward a block in DC differentiation in pB-ALL patients. In contrast, DC numbers in T-precursor ALL patients are increased and the cells do not exhibit functional alterations.
Materials and methods

Donor and patient samples
Peripheral blood from healthy children and ALL patients was obtained by phlebotomy following informed consent and approval by our institution's review board. All patients included in this study were treated on the ALL-BFM 2000 chemotherapy protocol. Clinical and disease parameters were retrieved from the ALL-BFM 2000 database. Peripheral blood mononuclear cells (PBMC) were purified by Ficoll-density centrifugation.
Flow cytometry
Peripheral blood mononuclear cells were preincubated with human IgG to block Fc receptors and stained with fluorochrome-conjugated antibodies against CD3, CD4, CD8 (Dako Corporation, Hamburg, Germany), CD11c, CD14, CD16, CD19, CD25, CD28, CD40, CD56, CD86, CD123, HLA-DR (BD Pharmingen, Heidelberg, Germany) and BDCA-1, BDCA-2, BDCA-3 (Miltenyi Biotech, Bergisch Gladbach, Germany). A cocktail of CD3, CD14, CD16 and CD19 was used to discriminate lineage-negative cells. Myeloid DC were characterized as lineage-/HLA-DR þ /CD11c þ and plasmacytoid DC (pDC) as lineage-/HLA-DR þ /BDCA2 þ . Samples were analyzed on a FACS Calibur flow cytometer using cellquest software (Becton Dickinson, Heidelberg, Germany). At least 10 000 events were acquired in healthy children and 50 000 in ALL patients.
Statistical analysis
The median proportion of pbDC was compared using MannWhitney test. Univariate analysis within the group of pB-ALL patients was performed using U-test, Fischer's test or Spearman's Rho correlation as indicated. A result is considered significant if Po0.05.
Results
Peripheral blood dendritic cells are markedly reduced in B-precursor acute lymphoblastic leukemia patients but elevated in T-precursor acute lymphoblastic leukemia patients
As published experience with respect to normal levels of pbDC in children is limited, 15, 16 we first analyzed pDC and mDC numbers in a cohort of 19 healthy children. No significant correlation of either mDC (median (range); 20 (2.3-52) mDC/ml, P ¼ 0.40) or pDC (16 (1.7-64) pDC/ml, P ¼ 0.79) with age could be demonstrated in these children (data not shown).
Next, we enumerated pbDC counts in pediatric patients presenting with ALL (Table 1) , analyzing patients with T-cell precursor ALL (pT-ALL, n ¼ 17) and patients with B-cell precursor ALL (pB-ALL, n ¼ 38) separately. Compared to healthy donors, patients with pB-ALL revealed a significant decrease in the number of mDC (median 2.2 (0-78) mDC/ml, P ¼ 0.0001) and pDC (0.5 (0-68) pDC/ml, P ¼ 0.0001) in peripheral blood (Figure 1a and b) . Within the group of B-cell precursor ALL patients, we found a group of patients characterized by a complete absence of mDC (n ¼ 6) or pDC (n ¼ 12). Interestingly, whereas numbers of mDC and pDC correlated well in healthy children (Figure 1c ), no correlation could be established in pB-ALL patients: three pB-ALL patients had neither mDC nor pDC detectable in their blood, whereas nine patients had normal mDC counts in the absence of pDC, and three patients had no detectable mDC; while pDC counts were within normal range (Figure 1d ).
In striking contrast to patients with pB-ALL, pT-ALL patients showed significantly elevated levels of mDC (median 98.5 (6.8-711) mDC/ml, P ¼ 0.003; Figure 1a ) and slightly elevated counts of pDC (28.4 (0-330) pDC/ml, P ¼ 0.022; Figure 1b) . Except for two patients with no detectable mDC in the peripheral blood, numbers of mDC and pDC correlated well (Figure 1e ). Thus, pbDC are normal or increased in children with pT-ALL whereas reduced or absent in pediatric pB-ALL patients.
In the following steps we further characterized pbDC in pT-ALL patients and sought to elucidate potential mechanisms of DC depletion in pB-ALL patients.
Correlation of peripheral dendritic cell numbers with monocyte and neutrophil counts
In view of these significant numerical alterations in the DC compartment, we reasoned that reduced DC numbers might reflect decreased myelopoiesis in patients with ALL. To elucidate this question, we correlated neutrophil and monocyte counts as surrogate markers of myelopoesis with DC counts in pT-ALL and pB-ALL patients, respectively.
In pT-ALL patients, mDC numbers correlated well with neutrophil counts (P ¼ 0.03; Figure 2a ) and monocytes (P ¼ 0.004; data not shown). For pDC, there was only a slight Dendritic cell deficiencies in pediatric ALL patients B Maecker et al trend of correlation with neutrophils (P ¼ 0.15; Figure 2b ) and monocytes (P ¼ 0.05; data not shown). In contrast, mDC in pB-ALL patients showed a slight trend of negative correlation with neutrophils (P ¼ 0.17; Figure 2c ) and monocytes (P ¼ 0.06; data not shown). No correlation at all could be demonstrated for pDC in pB-ALL patients (P ¼ 0.97 for neutrophils, Figure 2d ; P ¼ 0.99 for monocytes, data not shown). Similarly, in univariate analysis, reduced numbers of DC were not associated with hemoglobin levels, platelet counts or blast infiltration of bone marrow (Table 2a ). In summary, whereas levels of pbDC in pT-ALL patients seem to be correlated with intact myelopoeisis, decreased DC numbers in patients with pB-ALL cannot readily be explained by impaired bone marrow function.
Dendritic cells are phenotypically normal in pT-ALL patients
To further characterize pbDCs in pT-ALL patients, we next determined their surface marker expression by flow cytometry. Both mDC and pDC showed equivalent expression levels of costimulatory molecules CD40 and CD86 (Figure 3a and b) as well as MHC class II (not shown) in pT-ALL patients and healthy controls, respectively. Activation marker CD83 was almost absent on pbDC in both groups. Dzionek et al. 17 described different subsets of mDC in peripheral blood characterized by expression of BDCA-1 or BDCA-3. In our analysis, there was no difference in expression of either marker on pbDC between pT-ALL patients and healthy control donors (Figure 3c ). Based on our phenotypic analysis, we conclude that DCs in pT-ALL patients do not show altered activation/maturation levels.
Absence of mDC is associated with aberrant expression of myeloid markers CD13, CD33, and myeloperoxidase on leukemic blasts in pB-ALL patients
Owing to the limited numbers, DC could not be further analyzed in pB-ALL patients. We therefore sought to assess whether any biological features of ALL cells might be associated with the lack of DC in pB-ALL patients. No association of low DC numbers was found with patient's age or sex (data not shown).
In univariate analysis, patients with lack of mDC were significantly more likely to have an immunophenotype of common ALL (P ¼ 0.01; Table 2a), whereas there was no association between absence of pDC and immunophenotype. Table 2 Univariate analysis of mDC and pDC numbers and patient parameters in pB-ALL patients (a) Analysis of parameters at presentation using Fisher's test expressing myeloid markers CD13, CD33 and myeloperoxidase with mDC and pDC numbers mDCo2/ml mDCX2/ml P-value pDC ¼ 0/ml pDC40/ml P-value 
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Interestingly, aberrant expression of myeloid surface markers on leukemic blasts was significantly more frequent in patients lacking mDC in peripheral blood (P ¼ 0.03; Table 2a ). In particular, increasing percentage of blasts expressing CD13, CD33 and, to a lesser extent, myeloperoxidase was strongly associated with absence of mDC in pB-ALL patients (P ¼ 0.003 and 0.014, respectively; Table 2b ). This unexpected finding raises the hypothesis that in some cases of pB-ALL the physiological differentiation of a common myeloid progenitor cell might be blocked and differentiation might be skewed toward leukemia development. Furthermore, statistical analysis showed that patients with high peripheral leukocyte counts and high peripheral blast counts had significantly more mDC in the peripheral blood (P ¼ 0.01; Table 2a ). This phenomenon may just be related to high general cell turnover, as these patients also had higher levels of lactate dehydrogenase. However, the analysis did not reveal any statistically significant relation between low numbers of DC and response to initial prednisone treatment (Table 2a) . Similarly, there was no association to stratification into risk groups by minimal residual disease evaluation, and time of follow-up is currently too short to assess disease-free and overall survival.
Discussion
Dendritic cells play a critical role in the generation of antitumor immunity. Several studies have demonstrated numerical as well as functional abnormalities of DC in patients with cancer (for review see Gabrilovich 18 ), in particular acute leukemias. 11, 14 Among functional defects, there are decreased expression of MHC or co-stimulatory molecules, 19, 20 insufficient T-cell stimulatory capacity 20, 21 and accumulation of immature DC in cancer patients. 21 As patients with ALL display particularly poor antitumor immune responses, 6 we sought to investigate the DC compartment in pediatric patients.
Here, we report results of a study investigating frequency and phenotype of pbDCs in pediatric ALL patients and healthy agematched controls. Whereas patients with T-precursor ALL have elevated numbers of pbDC expressing normal levels of MHC, costimulatory, and activation markers, patients with B-precursor ALL show decreased or absent pbDC numbers. This dichotomy between B-and T-cell ALL clearly illustrates that B-lineage and T-lineage ALL are characterized by distinct tumor-host characteristics, a finding that has also been revealed by the analysis of genetic polymorphisms in cytokine genes. 22 Decreased numbers of DC could not be explained by mere bone marrow dysfunction owing to infiltration of leukemic blast cells, as we were unable to document a correlation between DC numbers and other myeloid cell numbers such as neutrophils and monocytes. Our data are in accordance with observations published by Mami et al., 14 who detected normal numbers of DC in adult and few pediatric pT-ALL patients but significantly reduced DC numbers in pB-ALL patients. This group was able to demonstrate apparently normal cytokine-secreting function of DC in T-ALL patients, which is paralleled by our findings of unchanged phenotypic characteristics of DC in pediatric pT-ALL patients.
Several lines of evidence demonstrate that lack of DC in pB-ALL patients is not merely a result of a general hypoplasia of bone marrow cell production: patients with lack of mDC or pDC did not differ from those with measurable DC with respect to neutrophil or platelet counts, hemoglobin levels or blast infiltration in the bone marrow. Interestingly, Mami et al.
14 were unable to generate either mDC or pDC from CD34 þ precursor cells from pB-ALL patients. In our studies, lack of mDC was significantly associated with aberrant expression of myeloid markers CD13, CD33, and myeloperoxidase on Bprecursor leukemic blasts. Moreover, the percentage of blasts expressing CD13, CD33, and myeloperoxidase, respectively, was inversely correlated with numbers of mDC in pB-ALL patients. Even though decreased numbers of DC were not due to global bone marrow dysfunction, this finding is consistent with the hypothesis that in some patients with B-precursor ALL leukemic cells or leukemia-derived factors may contribute to a block in mDC development. Furthermore, lack of mDC was more frequent in patients with an immunophenotype of common ALL, which is thought to arise from a more immature precursor than pce B ALL. In acute myeloid leukemia, Mohty 11 and colleagues demonstrated leukemia-associated cytogenetic alterations in pbDCs, a finding consistent with a common developmental origin of DCs and leukemia cells. Further confirmatory experimental studies are necessary to examine whether similar mechanisms may be operative in ALL patients.
In summary, we provide evidence for distinct DC aberrations in patients with ALL at time of diagnosis, bearing relevance for a refined understanding of tumor immunity and future development of immunotherapeutic strategies. In concert with other observations, such as cytokine gene polymorphisms in IFN-g 22 and IL-10 genes, 23 this finding substantiates the concept of immunosurveillance in B-precursor ALL. Dendritic cell deficiencies in pediatric ALL patients B Maecker et al
